Abstract:Introduction Gastric cancer (GC) is the fourth most common cancer and the third-leading cause of cancer-related deaths worldwide. Despite certain advances in chemotherapy regimens and targeted therapies, the 5 year survival of patients with advanced GC is disappointing. The positive results of the apatinib phase III trial have cast new light on treatment for patients with advanced gastric cancer (GC) refractory to two or more lines of prior systemic chemotherapies. However, a dose reduction or treatment interruption is required to prevent apatinib toxicity such as hand-foot skin reaction (HFSR), proteinuria, and hypertension. In addition, suitable biomarkers are not accessible for identifying the patients who are most likely to benefit from apatinib. Therefore, predictive biomarkers are urgently needed to reduce toxicity and identify patients that will benefit from apatinib treatment. Material and methods Clonogenic assay, cytotoxicity assay, apoptosis assay, qRT-PCR, western blot were conducted in GC cells to evaluate the effectiveness of apatinib in vitro. Confocal microscopy assay was peformed to examine apatinib-induced autophagic flux in GC cells. Transmission electron microscopy assay was conducted to show the formation of autophagic vesicles. Xenograft models in mice were conducted and six tumour tissues were sent for miRNA-seq and circRNA-seq. Sanger sequencing was applied to determine the full length of the amplification products. Results and discussions In this study, we found that apatinib inhibited the growth of GC cells and xenograft tumours. Apatinib promoted autophagy activation via upregulation of ATG7 expression, and autophagy inhibition enhanced apatinib-induced apoptosis. With miRNA-seq and circRNA-seq analyses of GC xenograft models, we demonstrated that circRNA004582 functioned as an endogenous sponge for miR-3657 to inhibit its activity and further upregulate ATG7 expression. Silencing of circRNA004582 inhibited apatinib-induced autophagy, which was rescued by miR-3657. Moreover, knockdown of circRNA004582 promoted apatinib-induced apoptosis in GC cells. These findings provided the first evidence that the circRNA004582-miR-3657-ATG7 axis mediates a regulatory pathway critical for the regulation of autophagy and apatinib sensitivity in GC cells and xenografts. Conclusion In conclusion, specific blockage of circRNA004582 may be a potential therapeutic target for autophagy inhibition in the context of apatinib treatment in human GC. Prospective clinical studies are warranted to examine these biomarkers.

AKAP8L Enhances the Stemness and Chemoresistance of Gastric Cancer Cells by Stabilizing SCD1 Mrna

APAF1‐Binding Long Noncoding RNA Promotes Tumor Growth and Multidrug Resistance in Gastric Cancer by Blocking Apoptosome Assembly

The APEX1/miRNA-27a-5p axis plays key roles in progression, metastasis and targeted chemotherapy of gastric cancer

IDDF2024-ABS-0392 Identification of MCM10 As a Key Effector of YAP1 Signaling That Promotes Cancer Stemness and Drug Resistance in Gastric Carcinogenesis

MCM8 promotes gastric cancer progression through RPS15A and predicts poor prognosis

Stearoyl-CoA-desaturase-1 Regulates Gastric Cancer Stem-Like Properties and Promotes Tumour Metastasis Via Hippo/YAP Pathway

Apolipoprotein C1 regulates gastric cancer progression by inducing epithelial-mesenchymal transition via the JAK/STAT pathway

SIRT1 Inhibits Chemoresistance and Cancer Stemness of Gastric Cancer by Initiating an AMPK/FOXO3 Positive Feedback Loop

ASB16-AS1 Up-Regulated and Phosphorylated TRIM37 to Activate NF-κB Pathway and Promote Proliferation, Stemness, and Cisplatin Resistance of Gastric Cancer

ABCG2 Confers Promotion in Gastric Cancer Through Modulating Downstream CRKL in Vitro Combining with Biostatistics Mining.

Evidence from Expression, Functional, and Bioinformatic Analyses

Krüppel-like Factor 8 Contributes to Hypoxia-Induced MDR in Gastric Cancer Cells.

ATXN2-Mediated PI3K/AKT Activation Confers Gastric Cancer Chemoresistance and Attenuates CD8+ T Cell Cytotoxicity

Shugoshin1 Enhances Multidrug Resistance of Gastric Cancer Cells by Regulating MRP1, Bcl-2, and Bax Genes

PAK6 promotes homologous-recombination to enhance chemoresistance to oxaliplatin through ATR/CHK1 signaling in gastric cancer

PO-071 Silencing of Circrna004582 Sensitises Gastric Cancer Cells to APATINIB Via Modulating Autophagy by Targeting Mir-3657 and ATG7

Inhibition of CCCTC Binding Factor-Programmed Cell Death Ligand 1 Axis Suppresses Emergence of Chemoresistance Induced by Gastric Cancer-Derived Mesenchymal Stem Cells.

AKR1C3 mediates gastric cancer cell invasion and metastasis via the AKT and JNK/p-NF-κB signaling pathways

Abstract 5872: CDK1-SOX9 axis contributes to chemotherapy resistance in gastric cancer

Silencing of Circracgap1 Sensitizes Gastric Cancer Cells to Apatinib Via Modulating Autophagy by Targeting Mir-3657 and ATG7

Targeting LGSN restores sensitivity to chemotherapy in gastric cancer stem cells by triggering pyroptosis